Transitional Cell Carcinoma
Showing 1 - 25 of >10,000
Transitional Cell Carcinoma Trial in New York (TICE®-strain BCG, NY-ESO-1 protein, sargramostim)
Completed
- Transitional Cell Carcinoma
- TICE®-strain BCG
- +2 more
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Oct 3, 2022
Urothelial Carcinoma, Urothelial Carcinoma Recurrent, Urothelial Carcinoma Ureter Trial (Jelmyto (mitomycin) for pyelocalyceal
Not yet recruiting
- Urothelial Carcinoma
- +7 more
- Jelmyto (mitomycin) for pyelocalyceal solution
- (no location specified)
May 22, 2023
Bladder Cancer, Metastatic Transitional Cell Carcinoma Trial in New York (Everolimus)
Completed
- Bladder Cancer
- Metastatic Transitional Cell Carcinoma
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 16, 2021
Ovarian Cancer, Fallopian Tube Adenocarcinoma, Fallopian Tube Carcinosarcoma Trial in Seattle (Exercise Counseling, Aerobic
Terminated
- Ovarian Cancer
- +21 more
- Exercise Counseling
- +5 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Oct 6, 2022
Bladder Transitional Cell Carcinoma, Bladder Cancer, Fibroblast Growth Factor Receptor Trial (Infigratinib)
Withdrawn
- Bladder Transitional Cell Carcinoma
- +2 more
- (no location specified)
Aug 8, 2022
Transitional Cell Carcinoma Trial in New Haven (Pembrolizumab and Ramucirumab)
Withdrawn
- Transitional Cell Carcinoma
- Pembrolizumab and Ramucirumab
-
New Haven, ConnecticutYale University
Feb 18, 2022
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor, Fallopian Tube Mucinous Tumor Trial in Rochester
Active, not recruiting
- Fallopian Tube Clear Cell Adenocarcinoma
- +22 more
- Laboratory Biomarker Analysis
- Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine
-
Rochester, MinnesotaMayo Clinic
Oct 7, 2022
Non-Transitional Cell Carcinoma of the Urothelial Tract, Small Cell of the Bladder, Adenocarcinoma of the Bladder Trial in
Completed
- Non-Transitional Cell Carcinoma of the Urothelial Tract
- +4 more
- durvalumab and tremelimumab
-
Basking Ridge, New Jersey
- +3 more
Nov 3, 2021
Metastatic Urothelial Carcinoma, Transitional Cell Carcinoma, Unresectable Transitional Cell Carcinoma Trial in Houston
Active, not recruiting
- Metastatic Urothelial Carcinoma
- +2 more
- Doxorubicin Hydrochloride
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 18, 2022
Urothelial Carcinoma of the Renal Pelvis and Ureter, Transitional Cell Cancer of the Renal Pelvis and Ureter Trial (ST-02)
Not yet recruiting
- Urothelial Carcinoma of the Renal Pelvis and Ureter
- Transitional Cell Cancer of the Renal Pelvis and Ureter
- (no location specified)
Nov 7, 2023
Carcinoma, Transitional Cell Trial in Beijing (nanoparticle albumin-bound paclitaxel, S-1, Gemcitabine, cisplatin)
Completed
- Carcinoma, Transitional Cell
- nanoparticle albumin-bound paclitaxel, S-1
- Gemcitabine, cisplatin
-
Beijing, ChinaChinese PLA General Hospital
Aug 5, 2021
Squamous Cell Carcinoma of Head and Neck, Colo-rectal Cancer, Non Small Cell Lung Cancer Trial in Aurora, Nashville, Houston
Recruiting
- Squamous Cell Carcinoma of Head and Neck
- +4 more
-
Aurora, Colorado
- +2 more
Apr 18, 2022
Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma Trial in
Recruiting
- Fallopian Tube Carcinosarcoma
- +28 more
- Pegylated Liposomal Doxorubicin Hydrochloride
- Peposertib
-
Aurora, Colorado
- +7 more
Sep 2, 2022
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma Trial in United States (biological, other,
Recruiting
- Cervical Adenocarcinoma
- +47 more
- Bevacizumab
- +3 more
-
Phoenix, Arizona
- +3 more
Dec 5, 2022
Bladder Cancer, Squamous Cell Carcinoma of the Bladder, Stage III Bladder Cancer Trial in Atlanta (3D conformal radiation
Terminated
- Bladder Cancer
- +4 more
- 3D conformal radiation therapy
-
Atlanta, GeorgiaEmory University Hospital/Winship Cancer Institute
Feb 14, 2022
Immunotherapy in Upper Tract Urothelial Carcinoma
Not yet recruiting
- Urothelial Carcinoma
- Evaluation of anti-PD-(L)1 immunotherapy efficacy
- (no location specified)
Oct 27, 2023
Metastatic Transitional Cell Carcinoma of the Urothelium Trial in United States (Buparlisib)
Completed
- Metastatic Transitional Cell Carcinoma of the Urothelium
-
Basking Ridge, New Jersey
- +4 more
May 26, 2021
Bladder Cancer, Urothelial Carcinoma Bladder Trial in Mumbai (Adjuvant RT)
Recruiting
- Bladder Cancer
- Urothelial Carcinoma Bladder
- Adjuvant RT
-
Mumbai, Maharashtra, IndiaTata Memorial Centre
Oct 6, 2021
18F-LN1 PET/CT in Urothelial Carcinomas
Recruiting
- Urothelial Carcinoma
-
Chengdu, Sichuan, ChinaDepartments of Nuclear Medicine, Sichuan Provincial People's Hos
Nov 2, 2023
Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma Trial in Tampa (Adoptive Cell Therapy with Tumor-infiltrating
Recruiting
- Urothelial Carcinoma
- Non-Invasive Bladder Urothelial Carcinoma
- Adoptive Cell Therapy with Tumor-infiltrating Lymphocytes (TIL)
-
Tampa, FloridaMoffitt Cancer Center
Mar 2, 2023
Transitional Cell Carcinoma, Advanced Cancer, Metastatic Cancer Trial in Austria, Germany (Nivolumab/Ipilimumab)
Active, not recruiting
- Transitional Cell Carcinoma
- +2 more
- Nivolumab/Ipilimumab
-
Graz, Austria
- +26 more
Nov 2, 2021
Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma Trial in Philadelphia (Enfortumab
Not yet recruiting
- Urothelial Carcinoma
- +2 more
- Enfortumab vedotin
- Pembrolizumab
-
Philadelphia, PennsylvaniaFox Chase Cancer Center - Philadelphia
Jun 27, 2023
Primary and Metastatic Tumors in Renal Cell Carcinoma and
Recruiting
- Renal Cell Carcinoma
- +4 more
- Immune checkpoint inhibitor targeting PD1
-
Philadelphia, PennsylvaniaFox Chase Cancer Center - Philadelphia
Jan 27, 2023
